Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX:BLCO), a $5.1 billion market cap eye care specialist with annual revenue of $4.83 billion, announced that its LUMIFY Preservative Free eye drops demonstrated equivalent effectiveness to the original LUMIFY formula in reducing ocular redness, according to Phase 3 clinical trial results published in Ophthalmology and Therapy.
The multicenter study involved 380 participants who received either LUMIFY Preservative Free or the original LUMIFY, administered four times daily for four weeks. Results confirmed that the preservative-free version was statistically non-inferior to the original formula in reducing eye redness, with comparable safety profiles between both products. The company has shown strong commercial execution, with revenue growing nearly 12% over the last twelve months and maintaining a healthy gross margin of 60%.
"The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease," said Melissa Toyos, MD, partner at Toyos Clinic in Nashville.
According to the company, LUMIFY products deliver noticeable results in one minute and last up to eight hours. The preservative-free version demonstrated a low incidence of side effects such as rebound redness when used as directed, similar to the original formula.
Launched in June 2025, LUMIFY Preservative Free joins Bausch + Lomb’s eye care portfolio, which includes approximately 400 products across various categories. The original LUMIFY, introduced in 2018, is formulated with low-dose brimonidine tartrate 0.025% that selectively targets eye redness.
John Ferris, president of Consumer at Bausch + Lomb, stated that the new preservative-free formula "provides a needed option for patients with eye sensitivities."
The information in this article is based on a press release from Bausch + Lomb Corporation. Investors can access detailed analysis and additional insights about BLCO’s performance through InvestingPro, which offers exclusive financial metrics and professional research reports. The company is scheduled to report its next earnings on July 30, 2025.
In other recent news, Bausch & Lomb Corp. announced amendments to the CEO Brenton L. Saunders’ contract, specifically altering his severance rights related to a potential spin-off from Bausch Health Companies Inc. The company also priced €675 million in senior secured floating rate notes due 2031, increasing the offering size from the previously announced €600 million. Additionally, Bausch & Lomb is seeking to partially refinance its credit agreement with a $2.325 billion new term B loan facility and an $800 million revolving credit facility. RBC Capital has reiterated its Outperform rating on Bausch & Lomb stock, projecting Q2/25 revenue of $1,283 million, slightly above the consensus estimate. Stifel maintained its Hold rating on the stock, expressing concerns about the company’s competitive position in key growth markets. Meanwhile, Barclays lowered its stock price target for Bausch & Lomb to $16, citing a reduction in the company’s projected next twelve months EBITDA to $996 million. The analysts at Barclays adjusted their evaluation due to changes in financial performance expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.